SCHEMBL8773483

SCHEMBL8773483

CN(CCO)c1ccc(C(=O)Nc2ccc(Oc3ccc(NC(=O)c4ccc(N(C)CCO)cc4)cc3)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.54
ALDH1A1 P00352 4/20 0.54
HSD17B10 Q99714 3/20 0.54
LMNA P02545 3/20 0.54
MAPT P10636 2/20 0.54
MCL1 Q07820 2/20 0.54
TP53 P04637 2/20 0.54
RAB9A P51151 5/20 0.54
TSHR P16473 2/20 0.54
PGR P06401 2/20 0.52
NPC1 O15118 4/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
ALOX15 P16050 1/20 0.51
KMT2A Q03164 2/20 0.49
TNIK Q9UKE5 1/20 0.48
HDAC1 Q13547 1/20 0.47
CYP1A2 P05177 1/20 0.47
MEN1 O00255 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1665050 0.87 RAB9A (0.53) KDM4EALDH1A1HSD17B10LMNAMAPT
SCHEMBL8770690 0.83 MAPT (0.76) KDM4EALDH1A1HSD17B10LMNAMAPT
SCHEMBL21254607 0.83 TNIK (0.47) KDM4EALDH1A1HSD17B10LMNAMAPT
SCHEMBL6126137 0.82 ALDH1A1 (0.45) KDM4EALDH1A1HSD17B10LMNAMAPT
SCHEMBL15218419 0.80 MAOB (0.60) KDM4EALDH1A1LMNAMAPTTP53
SCHEMBL21254714 0.80 TNIK (0.45) KDM4EALDH1A1HSD17B10LMNAMAPT
SCHEMBL19051895 0.78 MAPT (0.68) KDM4EALDH1A1HSD17B10LMNAMAPT
SCHEMBL15218178 0.77 ABCG2 (0.56) KDM4EALDH1A1HSD17B10MAPTMCL1
SCHEMBL10154271 0.76 L3MBTL1 (0.50) TSHRSMN1; SMN2TNIKHDAC1L3MBTL1
SCHEMBL1664454 0.76 RAB9A (0.52) KDM4EALDH1A1HSD17B10MAPTMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
WO-2012068406-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-05-24 WO disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL KDM4E 3484/4885ALDH1A1 3228/4885HSD17B10 4105/4885
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF KDM4E 1944/4885ALDH1A1 2736/4885HSD17B10 4495/4885
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF KDM4E 1944/4885ALDH1A1 2736/4885HSD17B10 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.